Reports Q3 revenue $38.44M, consensus $40.25M. “While revenue came in slightly below our expectations this quarter, we achieved another all-time record for consumable revenue, expanded gross margins and continued to reduce our operating expenses,” said Christian Henry, President and Chief Executive Officer. “We also reached an important milestone on our technology roadmap with the introduction of SPRQ-Nx chemistry, which we believe will help dramatically lower the cost of human genome sequencing and make our technology economically competitive with many short read sequencing platforms. These achievements underscore our focus on disciplined growth and our commitment to making PacBio’s (PACB) highly accurate long-read sequencing more accessible worldwide.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Cathie Wood Pours into Veracyte Stake ahead of Earnings Beat, Slashes Biotech Holdings
- PacBio announces publication of new preprint on HiFi sequencing
- PacBio supports Berry Genomics in achieving approval for sequencer in China
- PACB Upcoming Earnings Report: What to Expect?
- Cathie Wood Cuts Stakes in AMD and Palantir (PLTR) Stocks, Loads Up on Deere and Pacific Biosciences